A Novel Approach to Delivering Basal-Prandial Insulin
This article is written live from the American Association of Clinical Endocrinologists (AACE) 2017 Annual Meeting in Austin, TX. MPR will be reporting news on the latest findings from leading experts in endocrinology. Check back for more news from AACE 2017.
A recent retrospective analysis presented at the AACE 2017 Annual Meeting demonstrated that V-Go, a wearable device that delivers basal-prandial insulin, has proven “to be an effective and efficient advancement for insulin delivery in patients with type 2 diabetes.”
Electronic medical records were used to identify patients who switched from insulin delivered via syringe or pen to V-Go. Data analyzed included A1c, weight, and insulin dosing. Howard Harrison, Jr., MD, FACP, FACE, of Endocrinology Consults, in Virginia Beach, VA, noted that, “data were analyzed based on all patients and stratified for patients administering ≥2 insulin injections/day at baseline.”
At baseline, the average A1c for all patients was 9.6%. Results of the study found significant reductions in A1c after using V-Go for 15 and 34 weeks (P<0.001). The study authors reported that the average change in A1c from baseline for all patients at 15 and 34 weeks was -1.4% (95% CI: -1.7, 1.0%) and -1.4% (95% CI: -1.8, -1.1%), respectively. For patients administering ≥2 insulin injections per day, the average change in baseline at 15 weeks was -1.3% (95% CI: -1.7, -0.9%) and -1.4% (95% CI: -1.8, -1.0%) at 34 weeks.
A significant reduction was also seen in the total daily dose (TDD) for patients who had been previously administering ≥2 insulin injections per day. The TDD was reduced from 72U to 60U daily at 15 weeks and from 72U to 63U daily at 34 weeks (P=0.007). The authors did note observing a small change in weight as well (+2kg; P<0.001), however, stated that, “the small change in weight is not believed to be clinically relevant.”
Dr. Harrison concluded, “in this analysis, switching to V-Go resulted in significant and sustained A1c reductions across the entire patient population and significant reductions in TDD for patients administering ≥2 insulin injections/day.”
For continuous endocrine news coverage from the AACE 2017 Annual Meeting, check back to MPR's AACE page for the latest updates.